SCHEMBL2953480

SCHEMBL2953480

Fc1ccc(Oc2ccc3c(N4CCOCC4)nncc3c2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.53
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GPR6 P46095 1/20 0.40
PIK3CG P48736 1/20 0.39
TRPA1 O75762 1/20 0.39
LCK P06239 1/20 0.39
KIT P10721 1/20 0.39
KDR P35968 1/20 0.39
MAPK9 P45984 1/20 0.39
ADORA2A P29274 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TDO2 P48775 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LRRK2 Q5S007 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944698 0.88 MAPK14 (0.50) MAPK14KDM4EALDH1A1PIK3CGLCK
SCHEMBL2946003 0.71 MAPK14 (0.49) MAPK14KDM4EALDH1A1LCKKIT
SCHEMBL2954373 0.71 MAPK14 (0.49) MAPK14KDM4EALDH1A1NPSR1LCK
SCHEMBL2954669 0.70 SCN9A (0.46) ALDH1A1
SCHEMBL1357935 0.70 MAPK14 (0.59) MAPK14KDM4EALDH1A1PIK3CGMAPK9
SCHEMBL2671263 0.69 MAPK14 (1.00) MAPK14KDM4EALDH1A1NPC1RAB9A
SCHEMBL22440005 0.69 LMNA (0.63) MAPK14KDM4EALDH1A1LRRK2
SCHEMBL2952503 0.69 MAPK14 (0.69) MAPK14TRPA1LCKKITKDR
SCHEMBL600573 0.66 LMNA (0.53) MAPK14KDM4EALDH1A1LCKKIT
SCHEMBL30493094 0.66 MAPK14 (0.47) MAPK14KDM4EALDH1A1KDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US claimed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP claimed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO claimed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US claimed
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAPK14 293/4885KDM4E 929/4885ALDH1A1 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.